Japan Blood Plasma Market to Grow with a CAGR of 8.25% through 2030

Increasing Prevalence of Blood Disorders and Advancements in Plasma-Based Therapies are expected to drive the Japan Blood Plasma Market growth in the forecast period, 2026-2030

According to TechSci Research report, “Japan Blood Plasma Market – By Region, Competition Forecast & Opportunities, 2030F”, the Japan Blood Plasma Market stood at USD 1.40 Billion in 2024 and is anticipated to grow with a CAGR of 8.25% in the forecast period through 2030.

Government support and favorable reimbursement policies are pivotal in driving the growth of the blood plasma market in Japan. The Japanese healthcare system offers extensive coverage for plasma-derived therapies, which guarantees that patients have access to essential treatments. Additionally, government-backed initiatives that promote research and development, along with subsidies and funding for plasma collection centers, significantly bolster market expansion. Innovations in plasma collection and processing technologies are also playing a critical role in this growth. Advanced fractionation techniques, automated collection systems, and improved purification methods enhance both the efficiency and safety of plasma-derived product production. These technological advancements not only increase yield but also reduce production costs, thereby ensuring a reliable and high-quality supply of plasma products.

The rising demand for personalized medicine is another key driver of market growth. The shift towards personalized medicine—where treatments are tailored to individual patient profiles—is increasingly influencing the blood plasma market. Customized immunoglobulins and targeted clotting factors are examples of personalized approaches that are gaining traction. These tailored therapies enhance treatment efficacy and drive the demand for advanced plasma products, reflecting a significant trend towards individualized medical care.

The expansion of plasma collection centers across Japan further supports market growth. The development of these centers boosts the capacity for plasma collection and processing, thereby strengthening the supply chain. By improving infrastructure for plasma collection, companies can better meet the increasing demand for plasma-derived products, contributing to the overall growth of the market.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on " Japan Blood Plasma Market”

The Japan Blood Plasma Market is segmented into type, application, end user, regional distribution, and company.

Based on end user, the hospital segment has emerged as the predominant market leader, Hospitals are primary settings where plasma-derived therapies are extensively utilized for treating a range of conditions, including hemophilia, immune deficiencies, and liver diseases. Hospitals provide comprehensive care and are equipped to administer complex treatments, making them the largest end-user of plasma products. This high utilization drives the demand for a steady supply of plasma-derived therapies and underscores the segment's dominance in the market. Hospitals, particularly large and specialized medical centers, are equipped with advanced facilities and technologies necessary for the administration of plasma-derived therapies. This includes specialized infusion centers, advanced diagnostic equipment, and monitoring systems that are crucial for managing patients receiving plasma treatments. The capacity to offer these sophisticated services makes hospitals a dominant player in the market. Hospitals often operate under integrated care models that include not only treatment but also comprehensive patient management and follow-up. This integration enhances the efficiency and effectiveness of plasma-derived therapies, contributing to the significant volume of product usage within hospital settings. The holistic approach to patient care in hospitals drives higher demand for these therapies compared to other healthcare settings.

Hospitals are frequently involved in emergency and critical care scenarios where plasma-derived products are essential. For instance, plasma products are critical in emergency surgeries, trauma care, and intensive care units (ICUs) for managing severe bleeding and other life-threatening conditions. The high demand for plasma therapies in these critical situations reinforces the dominant role of hospitals in the market. Hospitals often establish long-term partnerships and procurement agreements with plasma product manufacturers and suppliers. These agreements ensure a reliable supply of plasma products and facilitate bulk purchasing, which further solidifies hospitals' position as the leading end-user in the market. Such partnerships also often involve exclusive or preferential access to the latest and most advanced plasma therapies.

Major companies operating in Japan Blood Plasma Market are:

• CSL
• Grifols, S.A.
• Octapharma AG
• Biotest AG
• Kedrion S.p.A

Download Free Sample Report

Customers can also request for 10% free customization on this report

“the Japan blood plasma market is poised for continued growth, driven by increasing demand for plasma-derived therapies, advancements in treatment technologies, and expanding healthcare needs. The market's robust expansion is supported by significant investments in manufacturing capacity, raising awareness and diagnostic capabilities, and a strong focus on patient-centric care. While challenges such as regulatory complexities and supply chain constraints persist, the overall outlook remains positive. Strategic investments, technological innovations, and supportive healthcare policies will likely sustain the market's upward trajectory, positioning it as a critical component of Japan's healthcare infrastructure and a key player in the global blood plasma industry.,” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Japan Blood Plasma Market, By Type (Albumin, Factor VIII, Factor IX, Immunoglobulin, Hyperimmune Globulin, Others), By Application (Hemophilia, Hypogammaglobulinemia, Immunodeficiency Diseases, Von Willebrand’s Disease, Others), By End User (Hospitals, Clinics, Others), By Region, Competition Forecast & Opportunities, 2020-2030F”, has evaluated the future growth potential of Japan Blood Plasma Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Japan Blood Plasma Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]